Stock Scorer

Outset Medical, Inc. (OM)

Outset Medical, Inc. reported revenue of 31.6M USD for the quarter ending 30 June 2026, up 0.7% from 31.4M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 31.6M +0.7%
Gross Profit Q2 '26 · ending 30 June 2026 13.3M +11.9%
Operating Income Q2 '26 · ending 30 June 2026 -15.7M —
Net Income Q2 '26 · ending 30 June 2026 -18M —
Cost of Revenue Q2 '26 · ending 30 June 2026 18.4M -6.1%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -9.6M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -9.7M —
Shares Outstanding Q2 '26 · ending 30 June 2026 18.6K +164.5%
EPS Q1 '21 · ending 31 March 2021 -9.47 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 119.5M-66.7M-81.7M-47.1M
20242024-12-31 113.7M-113.4M-128M-117.2M
20232023-12-31 130.4M-169.8M-172.8M-134.8M
20222022-12-31 115.4M-161M-163M-154.1M
20212021-12-31 102.6M-130.5M-131.9M-133.4M
20202020-12-31 49.9M-117.5M-121.5M-108.1M
20192019-12-31 15.1M-70.3M-68.3M-73.6M
20182018-12-31 2M-46.6M-49.8M-48.2M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3031.6M
Q1 '262026-03-3127.9M
Q4 '252025-12-3128.9M
Q3 '252025-09-3029.4M
Q2 '252025-06-3031.4M
Q1 '252025-03-3129.8M
Q4 '242024-12-3129.5M
Q3 '242024-09-3028.7M
Q2 '242024-06-3027.4M
Q1 '242024-03-3128.2M
Q4 '232023-12-3130.5M
Q3 '232023-09-3030.4M
Q2 '232023-06-3036M
Q1 '232023-03-3133.5M
Q4 '222022-12-3132M
Q3 '222022-09-3027.8M
Q2 '222022-06-3025.1M
Q1 '222022-03-3130.6M
Q4 '212021-12-3128.2M
Q3 '212021-09-3026.3M

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-3013.3M
Q1 '262026-03-3112.1M
Q4 '252025-12-3112.2M
Q3 '252025-09-3011.6M
Q2 '252025-06-3011.9M
Q1 '252025-03-3111.1M
Q4 '242024-12-3110.7M
Q3 '242024-09-309.8M
Q2 '242024-06-309.8M
Q1 '242024-03-318.2M
Q4 '232023-12-317.7M
Q3 '232023-09-307.2M
Q2 '232023-06-307.7M
Q1 '232023-03-316.4M
Q4 '222022-12-315.3M
Q3 '222022-09-304.3M
Q2 '222022-06-303.8M
Q1 '222022-03-314.4M
Q4 '212021-12-313.3M
Q3 '212021-09-302.9M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-15.7M
Q1 '262026-03-31-16.9M
Q4 '252025-12-31-17.6M
Q3 '252025-09-30-15.8M
Q2 '252025-06-30-16.9M
Q1 '252025-03-31-16.4M
Q4 '242024-12-31-21.9M
Q3 '242024-09-30-23.8M
Q2 '242024-06-30-30.8M
Q1 '242024-03-31-36.9M
Q4 '232023-12-31-37.4M
Q3 '232023-09-30-45.5M
Q2 '232023-06-30-43.5M
Q1 '232023-03-31-43.5M
Q4 '222022-12-31-39.8M
Q3 '222022-09-30-41M
Q2 '222022-06-30-43.7M
Q1 '222022-03-31-36.5M
Q4 '212021-12-31-40.8M
Q3 '212021-09-30-30.1M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-18M
Q1 '262026-03-31-19M
Q4 '252025-12-31-19.5M
Q3 '252025-09-30-17.8M
Q2 '252025-06-30-18.5M
Q1 '252025-03-31-25.8M
Q4 '242024-12-31-25.6M
Q3 '242024-09-30-27.9M
Q2 '242024-06-30-34.5M
Q1 '242024-03-31-39.9M
Q4 '232023-12-31-38.6M
Q3 '232023-09-30-46.2M
Q2 '232023-06-30-44M
Q1 '232023-03-31-44M
Q4 '222022-12-31-41.4M
Q3 '222022-09-30-40.8M
Q2 '222022-06-30-43.8M
Q1 '222022-03-31-36.9M
Q4 '212021-12-31-41.2M
Q3 '212021-09-30-30.5M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-3018.4M
Q1 '262026-03-3115.8M
Q4 '252025-12-3116.6M
Q3 '252025-09-3017.8M
Q2 '252025-06-3019.6M
Q1 '252025-03-3118.7M
Q4 '242024-12-3118.7M
Q3 '242024-09-3018.8M
Q2 '242024-06-3017.6M
Q1 '242024-03-3120M
Q4 '232023-12-3122.8M
Q3 '232023-09-3023.2M
Q2 '232023-06-3028.3M
Q1 '232023-03-3127M
Q4 '222022-12-3126.7M
Q3 '222022-09-3023.4M
Q2 '222022-06-3021.3M
Q1 '222022-03-3126.1M
Q4 '212021-12-3124.8M
Q3 '212021-09-3023.4M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-9.6M
Q1 '262026-03-31-12.8M
Q4 '252025-12-31-9.5M
Q3 '252025-09-30-6.3M
Q2 '252025-06-30-4.8M
Q1 '252025-03-31-25.7M
Q4 '242024-12-31-16.5M
Q3 '242024-09-30-20.6M
Q2 '242024-06-30-33.3M
Q1 '242024-03-31-45.9M
Q4 '232023-12-31-24.4M
Q3 '232023-09-30-34M
Q2 '232023-06-30-28.2M
Q1 '232023-03-31-44.8M
Q4 '222022-12-31-34.5M
Q3 '222022-09-30-34.3M
Q2 '222022-06-30-38.6M
Q1 '222022-03-31-38.3M
Q4 '212021-12-31-32.7M
Q3 '212021-09-30-28.1M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-9.7M
Q1 '262026-03-31-12.9M
Q4 '252025-12-31-9.7M
Q3 '252025-09-30-6.5M
Q2 '252025-06-30-5.1M
Q1 '252025-03-31-25.8M
Q4 '242024-12-31-16.5M
Q3 '242024-09-30-21M
Q2 '242024-06-30-33.5M
Q1 '242024-03-31-46.3M
Q4 '232023-12-31-25.5M
Q3 '232023-09-30-34.8M
Q2 '232023-06-30-29M
Q1 '232023-03-31-45.6M
Q4 '222022-12-31-36.6M
Q3 '222022-09-30-37.1M
Q2 '222022-06-30-40.6M
Q1 '222022-03-31-39.8M
Q4 '212021-12-31-33.5M
Q3 '212021-09-30-28.6M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3018.6K
Q1 '262026-03-3118.4K
Q3 '252025-09-3017.8K
Q2 '252025-06-3017.7K
Q1 '252025-03-317K
Q3 '242024-09-303.5K
Q2 '242024-06-303.5K
Q1 '242024-03-313.4K
Q3 '232023-09-3049.9K
Q2 '232023-06-3049K
Q1 '232023-03-3148.8K
Q3 '222022-09-3048.1K
Q2 '222022-06-3047.9K
Q1 '222022-03-3147.5K
Q3 '212021-09-3046.6K
Q2 '212021-06-3045.7K
Q1 '212021-03-3142.8M
Q1 '202020-03-315.6M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q1 '212021-03-31-9.47
Q4 '192019-12-31-89.38